Shareprice
22 Apr 2025

Pipeline

Our pipeline holds proprietary clinical-stage assets and projects in the preclinical and research phases, all aimed at developing and commercializing applications arising from our unique technology platform.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Pipeline

FluoGuide’s pipeline is in continuous development, with a primary focus on brain cancer and head and neck cancer. Additionally, the technology is being explored for use in photosensitizer therapy, highlighting its broader applicability across multiple cancer types.

Pre-clinical
Phase I
Phase II
Phase III
Commercial
FG001
Aggressive brain cancer (FGS)
Info
Next milestone: Consolidated plans
Head & Neck cancer (FGS)
Info
Next milestone: Consolidated plans
Lung cancer (FGS)
Info
Next milestone: Consolidated plans
Aggressive brain cancer (PTT)
Info
Next milestone: Consolidated plans
Progress